VERAXA Accelerates BiTAC Pipeline with Four TCEs, Targets IND Filing by 2028
VRXA•In H1 2026, VERAXA Biotech advanced four BiTAC-based T cell engager programs and two bispecific ADCs, securing heightened industry interest ahead of planned early monetization of non-BiTAC assets. The company aims to prioritize BiTAC investments and expects its first BiTAC-TCE candidate, VXA-102, IND/CTA-ready by early 2028.
1. H1 2026 Pipeline Advances
In the first half of 2026, VERAXA advanced four proprietary BiTAC-based T cell engager programs targeting solid tumors and progressed two bispecific ADC initiatives, including a strategic bsADC collaboration with OmniAb.
2. Strategic BiTAC Investment
The company plans to allocate the majority of R&D funding to its BiTAC portfolio, positioning these conditionally active T cell engagers as primary value drivers while seeking to monetize selected non-BiTAC assets to finance growth.
3. IND/CTA Milestone and Timeline
VERAXA aims to have its lead BiTAC-TCE candidate, VXA-102, ready for IND/CTA submission by early 2028, marking the first major regulatory milestone for its novel BiTAC technology.
4. Partnering Activity
Strong interest at industry conferences has bolstered ongoing discussions with potential collaborators, supporting the company’s goal to secure initial partnerships for both its BiTAC and ADC programs.
